Plasma S-100b Protein Concentration in Healthy Adults Is Age- and Sex-Independent

Wiesmann, Martin; Mißler, U.; Gottmann, D.; Gehring, Svante

doi:10.1093/clinchem/44.5.1056

Cited by 111 publications

(42 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma donors are on average younger than CJD patients. There is, however—at least for NSE, S‐100, and PrP c —little or no correlation between the concentrations of these proteins in CSF or plasma and the subject's age 20,45,46 . Because of the large difference between CRP and IL‐6 values in the control group and CJD patients, an influence of age also seems to be very unlikely for CRP and IL‐6.…”

Section: Discussionmentioning

confidence: 99%

C‐reactive protein and IL‐6: new marker proteins for the diagnosis of CJD in plasma?

et al. 2001

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

C‐reactive protein and IL‐6: new marker proteins for the diagnosis of CJD in plasma?

et al. 2001

View full text Add to dashboard Cite

show abstract

“…To define reference ranges for S100B and GFAP, blood samples of healthy blood donors were analysed as reported previously (17, 23). In the healthy subjects we found 0.060 ± 0.036 μg/l of S100B ( n = 197), and 0.006 ± 0.010 μg/l of GFAP ( n = 70).…”

Section: Methodsmentioning

confidence: 99%

Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP

Wiesmann

Steinmeier

Magerkurth

et al. 2010

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…As for S100 proteins, their median plasma concentration in healthy volunteers has been estimated to be 0.052 μg/L [45]. In other studies, the median serum level of S100A4 was found to be 11.8 (0-41.5) pg/mL, which was significantly lower than the level in patients with acute myocardial infarction (MI), 89.6 (4.3-214.6) pg/mL.…”

Section: Plasma Concentration Of Hmgb1 S100 Proteins Circulating Dnmentioning

confidence: 93%

Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution

Land

2020

Mol Diagn Ther

View full text Add to dashboard Cite

This opinion article discusses the increasing attention paid to the role of activating damage-associated molecular patterns (DAMPs) in initiation of inflammatory diseases and suppressing/inhibiting DAMPs (SAMPs) in resolution of inflammatory diseases and, consequently, to the future roles of these novel biomarkers as therapeutic targets and therapeutics. Since controlled production of DAMPs and SAMPs is needed to achieve full homeostatic restoration and repair from tissue injury, only their pathological, not their homeostatic, concentrations should be therapeutically tackled. Therefore, distinct caveats are proposed regarding choosing DAMPs and SAMPs for therapeutic purposes. For example, we discuss the need to a priori identify and define a context-dependent "homeostatic DAMP:SAMP ratio" in each case and a "homeostatic window" of DAMP and SAMP concentrations to guarantee a safe treatment modality to patients. Finally, a few clinical examples of how DAMPs and SAMPs might be used as therapeutic targets or therapeutics in the future are discussed, including inhibition of DAMPs in hyperinflammatory processes (e.g., systemic inflammatory response syndrome, as currently observed in , administration of SAMPs in chronic inflammatory diseases, inhibition of SAMPs in hyperresolving processes (e.g., compensatory antiinflammatory response syndrome), and administration/induction of DAMPs in vaccination procedures and anti-cancer therapy.

show abstract

Plasma S-100b Protein Concentration in Healthy Adults Is Age- and Sex-Independent

Cited by 111 publications

References 10 publications

C‐reactive protein and IL‐6: new marker proteins for the diagnosis of CJD in plasma?

C‐reactive protein and IL‐6: new marker proteins for the diagnosis of CJD in plasma?

Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP

Use of DAMPs and SAMPs as Therapeutic Targets or Therapeutics: A Note of Caution

Contact Info

Product

Resources

About